AstraZeneca Plc will likely get results of the company’s U.S. Covid-19 vaccine trial in late January 2021 and could potentially file for an emergency authorization, the chief adviser for the U.S. government’s Operation Warp Speed program said.
Auris Medical shares skyrocketed after the announcement of lab test results that appeared to show the company’s nasal spray AM-301 could potentially protect users against Covid-19, according to Business Insider.
Despite the constant need for social distancing, mask-wearing and the isolation and economic uncertainty that resulted from the Covid-19 outbreak, there is still much to be thankful for when families gather around a virtual table to break bread and carve the turkey this year.
AstraZeneca is likely to run an additional global trial to assess the efficacy of the company’s Covid-19 vaccine using a lower dosage, the British drugmaker’s chief executive was quoted as saying amid questions over the results of a late-stage study.
With all the expectations for available Covid-19 vaccines based on the successful late-stage trial results reported by Pfizer/BioNTech and Moderna, the looming question is: when will the public be able to start getting the vaccines?
BioSpace takes a look at Moderna at the similarities between the two, and a few differencesPfizer-BioNTech and Moderna Covid-19 vaccines preliminary data readout of its COVID-19 vaccine suggested a 90% efficacy rate, the U.S. and western countries have the promise of two effective and reasonably safe vaccines. There are . Here’s a look.